CN1686160A - 补充钙镁的药品制剂 - Google Patents
补充钙镁的药品制剂 Download PDFInfo
- Publication number
- CN1686160A CN1686160A CN 200510055746 CN200510055746A CN1686160A CN 1686160 A CN1686160 A CN 1686160A CN 200510055746 CN200510055746 CN 200510055746 CN 200510055746 A CN200510055746 A CN 200510055746A CN 1686160 A CN1686160 A CN 1686160A
- Authority
- CN
- China
- Prior art keywords
- calcium
- magnesium
- preparation
- additional
- medicine preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002360 preparation method Methods 0.000 title claims description 36
- ZFXVRMSLJDYJCH-UHFFFAOYSA-N calcium magnesium Chemical compound [Mg].[Ca] ZFXVRMSLJDYJCH-UHFFFAOYSA-N 0.000 title claims description 11
- 230000001502 supplementing effect Effects 0.000 title abstract 2
- 229910052791 calcium Inorganic materials 0.000 claims abstract description 74
- 229910052749 magnesium Inorganic materials 0.000 claims abstract description 25
- 239000003814 drug Substances 0.000 claims abstract description 12
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 72
- 239000011575 calcium Substances 0.000 claims description 72
- 229960005069 calcium Drugs 0.000 claims description 72
- CPLXHLVBOLITMK-UHFFFAOYSA-N Magnesium oxide Chemical compound [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 claims description 25
- 229940091250 magnesium supplement Drugs 0.000 claims description 24
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 23
- 239000011777 magnesium Substances 0.000 claims description 23
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 18
- 239000000395 magnesium oxide Substances 0.000 claims description 17
- 235000012245 magnesium oxide Nutrition 0.000 claims description 17
- 239000000843 powder Substances 0.000 claims description 15
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims description 14
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 14
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 claims description 14
- 239000008101 lactose Substances 0.000 claims description 14
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 claims description 14
- 239000007968 orange flavor Substances 0.000 claims description 14
- 229940013618 stevioside Drugs 0.000 claims description 14
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 claims description 14
- 235000019202 steviosides Nutrition 0.000 claims description 14
- 239000000470 constituent Substances 0.000 claims description 9
- 229960000869 magnesium oxide Drugs 0.000 claims description 9
- 235000019359 magnesium stearate Nutrition 0.000 claims description 9
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 claims description 9
- 239000000203 mixture Substances 0.000 claims description 9
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 8
- 229930195725 Mannitol Natural products 0.000 claims description 8
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 8
- 229920003081 Povidone K 30 Polymers 0.000 claims description 8
- 239000000594 mannitol Substances 0.000 claims description 8
- 235000010355 mannitol Nutrition 0.000 claims description 8
- 229910000019 calcium carbonate Inorganic materials 0.000 claims description 7
- 229960003563 calcium carbonate Drugs 0.000 claims description 7
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 6
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 claims description 6
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims description 4
- 239000002671 adjuvant Substances 0.000 claims description 4
- 239000001110 calcium chloride Substances 0.000 claims description 4
- 229910001628 calcium chloride Inorganic materials 0.000 claims description 4
- 229960002713 calcium chloride Drugs 0.000 claims description 4
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 claims description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 claims description 3
- 108010033929 calcium caseinate Proteins 0.000 claims description 3
- 239000004227 calcium gluconate Substances 0.000 claims description 3
- 235000013927 calcium gluconate Nutrition 0.000 claims description 3
- 229960004494 calcium gluconate Drugs 0.000 claims description 3
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 claims description 3
- NEEHYRZPVYRGPP-UHFFFAOYSA-L calcium;2,3,4,5,6-pentahydroxyhexanoate Chemical compound [Ca+2].OCC(O)C(O)C(O)C(O)C([O-])=O.OCC(O)C(O)C(O)C(O)C([O-])=O NEEHYRZPVYRGPP-UHFFFAOYSA-L 0.000 claims description 3
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 claims description 3
- 239000001095 magnesium carbonate Substances 0.000 claims description 3
- 229910000021 magnesium carbonate Inorganic materials 0.000 claims description 3
- 235000014380 magnesium carbonate Nutrition 0.000 claims description 3
- 229910001629 magnesium chloride Inorganic materials 0.000 claims description 3
- 229960002337 magnesium chloride Drugs 0.000 claims description 3
- 235000011147 magnesium chloride Nutrition 0.000 claims description 3
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims description 3
- 239000001736 Calcium glycerylphosphate Substances 0.000 claims description 2
- VSGNNIFQASZAOI-UHFFFAOYSA-L calcium acetate Chemical compound [Ca+2].CC([O-])=O.CC([O-])=O VSGNNIFQASZAOI-UHFFFAOYSA-L 0.000 claims description 2
- 239000001639 calcium acetate Substances 0.000 claims description 2
- 235000011092 calcium acetate Nutrition 0.000 claims description 2
- 229960005147 calcium acetate Drugs 0.000 claims description 2
- 239000011692 calcium ascorbate Substances 0.000 claims description 2
- 235000010376 calcium ascorbate Nutrition 0.000 claims description 2
- 229940047036 calcium ascorbate Drugs 0.000 claims description 2
- FNAQSUUGMSOBHW-UHFFFAOYSA-H calcium citrate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FNAQSUUGMSOBHW-UHFFFAOYSA-H 0.000 claims description 2
- 239000001354 calcium citrate Substances 0.000 claims description 2
- 229960004256 calcium citrate Drugs 0.000 claims description 2
- UHHRFSOMMCWGSO-UHFFFAOYSA-L calcium glycerophosphate Chemical compound [Ca+2].OCC(CO)OP([O-])([O-])=O UHHRFSOMMCWGSO-UHFFFAOYSA-L 0.000 claims description 2
- 229940095618 calcium glycerophosphate Drugs 0.000 claims description 2
- 235000019299 calcium glycerylphosphate Nutrition 0.000 claims description 2
- MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 claims description 2
- 239000001527 calcium lactate Substances 0.000 claims description 2
- 235000011086 calcium lactate Nutrition 0.000 claims description 2
- 229960002401 calcium lactate Drugs 0.000 claims description 2
- 239000001362 calcium malate Substances 0.000 claims description 2
- OLOZVPHKXALCRI-UHFFFAOYSA-L calcium malate Chemical compound [Ca+2].[O-]C(=O)C(O)CC([O-])=O OLOZVPHKXALCRI-UHFFFAOYSA-L 0.000 claims description 2
- 229940016114 calcium malate Drugs 0.000 claims description 2
- 235000011038 calcium malates Nutrition 0.000 claims description 2
- 239000001506 calcium phosphate Substances 0.000 claims description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 claims description 2
- 229960001714 calcium phosphate Drugs 0.000 claims description 2
- 235000011010 calcium phosphates Nutrition 0.000 claims description 2
- 229940095672 calcium sulfate Drugs 0.000 claims description 2
- 235000011132 calcium sulphate Nutrition 0.000 claims description 2
- BLORRZQTHNGFTI-ZZMNMWMASA-L calcium-L-ascorbate Chemical compound [Ca+2].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] BLORRZQTHNGFTI-ZZMNMWMASA-L 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 235000019700 dicalcium phosphate Nutrition 0.000 claims description 2
- MHJAJDCZWVHCPF-UHFFFAOYSA-L dimagnesium phosphate Chemical compound [Mg+2].OP([O-])([O-])=O MHJAJDCZWVHCPF-UHFFFAOYSA-L 0.000 claims description 2
- 229910000395 dimagnesium phosphate Inorganic materials 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 229960001708 magnesium carbonate Drugs 0.000 claims description 2
- 239000004337 magnesium citrate Substances 0.000 claims description 2
- 229960005336 magnesium citrate Drugs 0.000 claims description 2
- 235000002538 magnesium citrate Nutrition 0.000 claims description 2
- 239000001755 magnesium gluconate Substances 0.000 claims description 2
- 235000015778 magnesium gluconate Nutrition 0.000 claims description 2
- 229960003035 magnesium gluconate Drugs 0.000 claims description 2
- 239000011742 magnesium glycerophosphate Substances 0.000 claims description 2
- 235000001130 magnesium glycerophosphate Nutrition 0.000 claims description 2
- OVGXLJDWSLQDRT-UHFFFAOYSA-L magnesium lactate Chemical compound [Mg+2].CC(O)C([O-])=O.CC(O)C([O-])=O OVGXLJDWSLQDRT-UHFFFAOYSA-L 0.000 claims description 2
- 239000000626 magnesium lactate Substances 0.000 claims description 2
- 235000015229 magnesium lactate Nutrition 0.000 claims description 2
- 229960004658 magnesium lactate Drugs 0.000 claims description 2
- GVALZJMUIHGIMD-UHFFFAOYSA-H magnesium phosphate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O GVALZJMUIHGIMD-UHFFFAOYSA-H 0.000 claims description 2
- 239000004137 magnesium phosphate Substances 0.000 claims description 2
- 229910000157 magnesium phosphate Inorganic materials 0.000 claims description 2
- 229960002261 magnesium phosphate Drugs 0.000 claims description 2
- 235000010994 magnesium phosphates Nutrition 0.000 claims description 2
- IAKLPCRFBAZVRW-XRDLMGPZSA-L magnesium;(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanoate;hydrate Chemical compound O.[Mg+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O IAKLPCRFBAZVRW-XRDLMGPZSA-L 0.000 claims description 2
- BHJKUVVFSKEBEX-UHFFFAOYSA-L magnesium;2,3-dihydroxypropyl phosphate Chemical compound [Mg+2].OCC(O)COP([O-])([O-])=O BHJKUVVFSKEBEX-UHFFFAOYSA-L 0.000 claims description 2
- 229940049920 malate Drugs 0.000 claims description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 235000013337 tricalcium citrate Nutrition 0.000 claims description 2
- PLSARIKBYIPYPF-UHFFFAOYSA-H trimagnesium dicitrate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O PLSARIKBYIPYPF-UHFFFAOYSA-H 0.000 claims description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 7
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 7
- 239000008108 microcrystalline cellulose Substances 0.000 description 7
- 229940016286 microcrystalline cellulose Drugs 0.000 description 7
- 206010006956 Calcium deficiency Diseases 0.000 description 6
- 238000010521 absorption reaction Methods 0.000 description 6
- 230000003203 everyday effect Effects 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 239000002552 dosage form Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 235000016709 nutrition Nutrition 0.000 description 4
- 208000001132 Osteoporosis Diseases 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 230000035764 nutrition Effects 0.000 description 3
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 230000000474 nursing effect Effects 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 230000035935 pregnancy Effects 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 101710205660 Calcium-transporting ATPase Proteins 0.000 description 1
- 101710134161 Calcium-transporting ATPase sarcoplasmic/endoplasmic reticulum type Proteins 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108010007622 LDL Lipoproteins Proteins 0.000 description 1
- 102000007330 LDL Lipoproteins Human genes 0.000 description 1
- 208000008930 Low Back Pain Diseases 0.000 description 1
- 208000008167 Magnesium Deficiency Diseases 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000005842 biochemical reaction Methods 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000004097 bone metabolism Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- YYRMJZQKEFZXMX-UHFFFAOYSA-L calcium bis(dihydrogenphosphate) Chemical compound [Ca+2].OP(O)([O-])=O.OP(O)([O-])=O YYRMJZQKEFZXMX-UHFFFAOYSA-L 0.000 description 1
- 230000004856 capillary permeability Effects 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 201000005577 familial hyperlipidemia Diseases 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 238000003837 high-temperature calcination Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 108010022197 lipoprotein cholesterol Proteins 0.000 description 1
- 235000004764 magnesium deficiency Nutrition 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 201000011461 pre-eclampsia Diseases 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 235000021139 traditional diet Nutrition 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 235000000112 undernutrition Nutrition 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
本发明公开了一种补充钙镁的药品制剂，该制剂中含有钙剂、镁剂和辅料，钙剂和镁剂所含有的钙元素和镁元素在制剂中的重量含量分别为：钙元素17－23％、镁元素8.5－11.5％。本发明的补钙制剂具有吸收和转化效果好、成本低、无副作用的优点。
Description
技术领域
本发明涉及一种补钙药品，用于儿童、青少年、妊娠、哺乳妇女、更年期妇女、中老年人等的钙补充剂，也用于预防骨质疏松症。
背景技术
钙是人体必需的矿物质，99％存在于骨骼和牙齿中，其中1％的钙分布在软组织和细胞外液中。钙不仅构成了人体的骨架，而且对人体的神经、肌肉的应激冲动传递、心脏节律的维持、保持细胞膜的完整性和通透性、维持体内的酸碱平衡、血液的凝固都起着无法替代的重要作用，而且钙可降低毛细血管的通透性、防止渗出，控制炎症与水肿。
2000年，中国营养学会正式修订和通过了“中国居民膳食营养素参考摄入标准(DRIs)”。在这标准中，钙的每日推荐供给量为：18-49岁800mg；50岁以上1000mg。
我国90年代营养调查显示，我国属于低钙摄入的国家。我国居民每日钙平均摄入量500mg左右，不少省份低于400mg，此值不足生理供给量的50％，还远低于1990年中国营养学会修订的有关营养素膳食推荐量标准(RDA)中规定的成人每日800mg的标准；更低于西方一些国家每日摄入1000-1200mg的标准。
人体钙摄入不足，会影响身体发育，并可致多种疾病。孕妇严重缺钙则发生抽搐、妊高症等；中老年缺钙则会导致高血压、动脉硬化和关节腰腿痛；而最为普遍的发生的则是中老年人的骨质疏松综合症。钙的营养不足不仅是儿童，也成为中老年群体的重要营养问题。
人体所需要的钙主要来自于食物，我国是植物食物为主的传统膳食结构的国家，服乳制品较少。目前人们已意识到低钙摄入的危险性，不仅食物中钙补充受到广泛重视，钙剂在用于治疗的同时也开始用于缺钙的预防性补充。
钙的补充可分为针对缺钙人群的预防性补钙，针对与缺钙相关疾病有关联的特殊人群进行保健性补钙，针对疾病人群进行治疗性补钙。
然而，现有的钙剂也存在一些不足，主要表现在补钙过程中，特别是在保健性补钙和治疗性补钙中，一部分人会出现补钙效果不明显的问题，主要是人体对钙的吸收和转化利用效果不好。
发明内容
针对目前的钙剂存在的上述不足以及人们对钙摄入量的不足，本发明的目的在于提供一种易于吸收和转化、无不良反应且成本较低的钙剂。
本发明提供的补充钙镁的药品制剂，该制剂中含有钙剂和镁剂和辅料，钙剂和镁剂所含有的钙元素和镁元素在制剂中的重量含量分别为：钙元素17-23％、镁元素8.5-11.5％。
所述的钙剂和镁剂所含有的钙元素和镁元素计在制剂中的最佳重量含量分别为：钙元素20％、镁元素10％。
所述的钙剂可以为醋酸钙、碳酸钙、酪蛋白钙(酪朊钙)、氯化钙、柠檬酸钙、柠檬酸苹果酸钙、葡萄糖酸钙、乳酸钙、苹果酸钙、磷酸氢钙(二代磷酸钙)、磷酸二氢钙(一代磷酸钙)、磷酸钙(正磷酸钙)、硫酸钙、抗坏血酸钙、甘油磷酸钙、生物钙中的一种或多种。生物钙是指以海洋生物的壳经高温煅烧而得到的钙或者以动物骨粉为原料的钙剂，
所述的镁剂可以为氧化镁、碳酸镁、氯化镁、柠檬酸镁、葡萄糖酸镁、乳酸镁、磷酸氢镁、磷酸镁、甘油磷酸镁中的一种或多种。
所述的剂型可以为颗粒剂、片剂、粉剂、胶囊等现有的剂型。
选择的剂型优选为片剂，其中辅料由适量的乳糖和甘露醇、甜菊糖、甜橙香精粉末、5％PVP-K30(吡咯烷酮)、硬脂酸镁组成。
做为一种优选的实施方式，所述的乳糖、甜菊糖、甜橙香精粉末在片剂中的重量含量分别为：乳糖10-12％、甜菊糖0.25-0.6％、甜橙香精粉末0.5-1％。这种片剂，以乳糖、甜菊糖、甜橙香精三种作为矫味剂并精选其用量，口味好，相对于现有的补钙制剂来说，更容易被儿童接受。
对于片剂，每片重量为1.5g，成人每日2片，分1-2次服用。儿童一日1片，一日一次。对于其它剂型，每日的服用量可按上述片剂每天的钙元素摄入量标准服用。
这种补钙制剂，适用于儿童、青少年、妊娠、哺乳妇女、更年期妇女、中老年人等的钙补充剂，也用于预防骨质疏松症。
本发明的补钙制剂的有益效果是：
(1)镁是人体必需的常量元素，是骨和齿的重要成分之一。补钙的关键在吸收，钙吸收受多种因素的影响，钙与镁的关系十分密切，镁缺乏则钙吸收不良，镁能够促进钙的吸收利用，还与镁一起催化、激活多种酶的活性，参与许多与骨代谢有关的生化反应，它是一个促进钙吸收的重要元素。没有足够的镁，钙不能充分吸收。镁在控制钙的摄入、含量、结合以及重新分布上有重要作用，镁的运输依赖钙泵，而钙的代谢依赖镁的调节，低镁时可增强钙的内向流，高镁时阻滞钙的内向流，故镁与钙必须平衡，补钙的同时也应补镁，防止低镁高钙。本发明的补钙制剂，由于含有氧化镁，且钙与镁的用量合理，在补钙同时又补充了镁，能够恢复体内两种离子的平衡，促进了钙的吸收和代谢，因此补钙效果好。
(2)镁对心血管具有明显的保护作用，因此本发明的补钙制剂在补钙的同时可明显提高高密度脂蛋白水平，同时显著降低甘油三脂、胆固醇与低密度脂蛋白水平，从而有效地防治高脂血症及其继发的动脉粥样硬化，进而保护心脑器官。
(3)制成片剂，便于包装、储存及服用，加入合理的微晶纤维素，有利于崩解吸收。
(4)当采用片剂时，本发明还精选了乳糖、甜菊糖、甜橙香精粉末作为矫味剂，并通过三种矫味剂的合理搭配，使这种片剂口味好，特别适合于儿童补钙用。
具体实施方式
下面结合具体实施例对本发明的补充钙镁的药品制剂作进一步说明。
实施例1
将碳酸钙75g、氧化镁25g、微晶纤维素15g、乳糖17.3g、甘露醇15g、甜菊糖0.45g、甜橙香精粉末0.75g、硬脂酸镁1.5g及5％PVP-K30适量制成100片片剂。
实施例2
将氯化钙95g、氧化镁21.1g、微晶纤维素10g、乳糖10.2g、甘露醇11g、甜菊糖0.45g、甜橙香精粉末0.75g、硬脂酸镁1.5g及5％PVP-K30适量制成100片片剂。
实施例3
葡萄糖酸钙16.1g、将氯化钙71.4g、氧化镁28.6g、微晶纤维素10g、乳糖10.2g、甘露醇11g、甜菊糖0.45g、甜橙香精粉末0.75g、硬脂酸镁1.5g及5％PVP-K30适量制成100片片剂。
实施例4
将磷酸二氢钙40克、碳酸钙48.5g、氯化镁30g、碳酸镁30、硬脂酸镁1.5g，研细过筛，混合均匀装胶囊。
实施例5
将碳酸钙75g、氧化镁25g、微晶纤维素15g、乳糖17g、甘露醇14.1g、甜菊糖0.9g、甜橙香精粉末0.75g、5％PVP-K30适量、硬脂酸镁1.5g制片，共制100片
实施例6
将碳酸钙75g、氧化镁25g、微晶纤维素15g、乳糖15g、甘露醇15g、甜菊糖1g、甜橙香精粉末2.5g、5％PVP-K30适量、硬脂酸镁1.5g，共制100片片剂
实施例7
将碳酸钙75g、氧化镁25g、微晶纤维素15g、乳糖16g、甘露醇15g、甜菊糖1g、甜橙香精粉末1.5g、5％PVP-K30适量、硬脂酸镁1.5g，制成100片片剂。
Claims (7)
1、一种补充钙镁的药品制剂，其特征在于，该制剂中含有钙剂和镁剂和辅料，钙剂和镁剂所含有的钙元素和镁元素在制剂中的重量含量分别为：钙元素17-23％、镁元素8.5-11.5％。
2、如权利要求1所述的补充钙镁的药品制剂，其特征在于，所述的钙剂和镁剂所含有的钙元素和镁元素计在制剂中的重量含量分别为：钙元素20％、镁元素10％。
3、如权利要求1或2所述的补充钙镁的药品制剂，其特征在于：所述的钙剂为醋酸钙、碳酸钙、酪蛋白钙、氯化钙、柠檬酸钙、柠檬酸苹果酸钙、葡萄糖酸钙、乳酸钙、苹果酸钙、磷酸氢钙、磷酸二氢钙、磷酸钙、硫酸钙、抗坏血酸钙、甘油磷酸钙、生物钙中的一种或多种。
4、如权利要求1或2所述的补充钙镁的药品制剂，其特征在于：所述的所述的镁剂为氧化镁、碳酸镁、氯化镁、柠檬酸镁、葡萄糖酸镁、乳酸镁、磷酸氢镁、磷酸镁、甘油磷酸镁中的一种或多种。
5、如权利要求1或2所述的补充钙镁的药品制剂，其特征在于：该制剂为片剂或颗粒剂、胶囊。
6、如权利要求5所述的补充钙镁的药品制剂，其特征在于：为片剂，其中辅料由适量的乳糖和甘露醇、甜菊糖、甜橙香精粉末、5％PVP-K30、硬脂酸镁组成。
7、如权利要求6所述的补充钙镁的药品制剂，其特征在于，所述的乳糖、甜菊糖、甜橙香精粉末在片剂中的重量含量分别为：乳糖10-12％、甜菊糖0.25-0.6％、甜橙香精粉末0.5-1％。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005100557463A CN100515429C (zh) | 2005-03-21 | 2005-03-21 | 补充钙镁的药品制剂 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005100557463A CN100515429C (zh) | 2005-03-21 | 2005-03-21 | 补充钙镁的药品制剂 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1686160A true CN1686160A (zh) | 2005-10-26 |
| CN100515429C CN100515429C (zh) | 2009-07-22 |
Family
ID=35304202
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2005100557463A Expired - Fee Related CN100515429C (zh) | 2005-03-21 | 2005-03-21 | 补充钙镁的药品制剂 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100515429C (zh) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101537170B (zh) * | 2008-03-17 | 2012-05-30 | 哈药集团制药六厂 | 一种预防骨质疏松和骨关节病的组合物 |
| CN107114795A (zh) * | 2017-07-06 | 2017-09-01 | 胥永贵 | 一种弱碱补钙、苏打碱化姜制剂及其制备方法和应用 |
| CN110354138A (zh) * | 2019-07-18 | 2019-10-22 | 宿迁市现代生物科技股份有限公司 | 一种低磨耗的可直接压片的颗粒碳酸钙的配方 |
| CN117982533A (zh) * | 2024-04-03 | 2024-05-07 | 济南深蓝动物保健品有限公司 | 一种复合钙制剂及其生产工艺 |
-
2005
- 2005-03-21 CN CNB2005100557463A patent/CN100515429C/zh not_active Expired - Fee Related
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101537170B (zh) * | 2008-03-17 | 2012-05-30 | 哈药集团制药六厂 | 一种预防骨质疏松和骨关节病的组合物 |
| CN107114795A (zh) * | 2017-07-06 | 2017-09-01 | 胥永贵 | 一种弱碱补钙、苏打碱化姜制剂及其制备方法和应用 |
| CN110354138A (zh) * | 2019-07-18 | 2019-10-22 | 宿迁市现代生物科技股份有限公司 | 一种低磨耗的可直接压片的颗粒碳酸钙的配方 |
| CN117982533A (zh) * | 2024-04-03 | 2024-05-07 | 济南深蓝动物保健品有限公司 | 一种复合钙制剂及其生产工艺 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN100515429C (zh) | 2009-07-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5756469A (en) | Composition of pyruvate and anti-cortisol compounds and method for increasing protein concentration in a mammal | |
| CN100515430C (zh) | 补充钙镁和维生素d的药品制剂 | |
| CN105412406A (zh) | 一种降低血液粘稠度的中药组合物及其制备方法 | |
| CN101040710A (zh) | 一种内服调节女士内分泌兼外用美容养颜的保健营养冲剂 | |
| CN100418548C (zh) | 一种药用组合物及其用途 | |
| KR20020006114A (ko) | 체내에 흡수되기 용이한 단백화-아연의 제조방법 | |
| JP2011510922A (ja) | 骨粗鬆症の予防及び回復のためのカルシウム、マグネシウム、亜鉛、ビタミンｄ３を含む調剤 | |
| CN100515429C (zh) | 补充钙镁的药品制剂 | |
| CN101279089B (zh) | 阿胶钙组合物及其制备方法 | |
| KR20070113460A (ko) | 체중조절용 건강식품 조성물 | |
| KR20010066713A (ko) | 다이어트 인삼제품 제조방법 | |
| CN110214938A (zh) | 用于糖尿病人群的特殊医学用途配方营养粉及其制备方法 | |
| CN108125941A (zh) | 一种e-10-羟基-2-癸烯酸在制备防治骨质疏松症的药品或保健品中的应用 | |
| CN101129406A (zh) | 复方阿胶系列产品的配方和制造方法 | |
| CN1679593A (zh) | 一种含有α－亚麻酸游离酸、大豆磷脂和维生素E的复合制剂 | |
| CN107595829B (zh) | 一种防治肾性骨营养不良的组合物 | |
| CN1090464C (zh) | 一种降糖保健食盐及其制备方法 | |
| JPH09238615A (ja) | 健康栄養食品 | |
| CN102151285B (zh) | 中性补钙制剂 | |
| CN101019846A (zh) | 含丙酮酸及其盐的胶囊的制备 | |
| CN1431002A (zh) | 一种蜂胶降糖降脂保健组合物及其胶囊的制造方法 | |
| CN1883593A (zh) | 九味补血口服液 | |
| CN1305400C (zh) | 黑木耳燕麦羹及其制备方法 | |
| CN1050035C (zh) | 营养保健蜂蜜的生产方法 | |
| CN101204400A (zh) | 阿胶系列产品的配方和制造方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| ASS | Succession or assignment of patent right |
Owner name: HUNAN THEIL PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: CHENG GANG Effective date: 20080404 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20080404 Address after: Liuyang City, Hunan Province, North Li Qiao bridge, Hunan, Changsha mailbox, code: 410011 Applicant after: Hunan Taier Pharmaceutical Company Limited Address before: Hunan province Changsha Shinan District South Road No. 179 post encoding: 410000 Applicant before: Cheng Gang |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Medicinal preparation for supplementing calcium magnesium Effective date of registration: 20150212 Granted publication date: 20090722 Pledgee: Bank of Beijing Limited by Share Ltd Changsha branch Pledgor: Hunan Taier Pharmaceutical Company Limited Registration number: 2015430000004 |
|
| PP01 | Preservation of patent right |
Effective date of registration: 20161107 Granted publication date: 20090722 |
|
| RINS | Preservation of patent right or utility model and its discharge | ||
| PD01 | Discharge of preservation of patent | ||
| PD01 | Discharge of preservation of patent |
Date of cancellation: 20191107 Granted publication date: 20090722 |
|
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20090722 Termination date: 20210321 |